CVR Medical (TSX.V:CVM and OTCQB CRRVF) has a device currently in clinical trials that can potentially measure how stenosed arteries are much cheaper and faster than current methods/tests. Peter Bakema, President and CEO of CVR joins me today to outline the device that is currently in clinical trails and outlines the path to market that he is hoping will be early next year.
CVR also issued news today regarding the implementation of the wireless system. Click here to view the full news releases.
Click here to visit the CVR website for more information on the Company and the device.
Click download link to listen on this device: Download Show